title: Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate.
abstract: OBJECTIVE
  To assess the long-term sexual potency and attrition in sexual function after iodine-125 ((125)I) seed radiotherapy and the effect of sildenafil on radiation-induced erectile dysfunction (ED).
  
  
  METHODS
  This prospective study consisted of 86 sexually active patients (mean age 63.5 +/- 7.7 years) who underwent (125)I seed implantation from 1997 to 1999 to treat low-volume prostate cancer (prostate-specific antigen less than 10 ng/mL, Gleason score 6 or less, stage T1-T2). All patients were followed up every 6 to 8 months for 4 years. Patients prescribed sildenafil citrate for ED completed the abridged five-item version of the International Index of Erectile Function (IIEF) and the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaires.
  
  
  RESULTS
  The median follow-up was 49.7 months (range 36 to 66). Of 86 patients, 43 (50%) did not initiate drug therapy; and only 36 (83.7%) of the 43 were interviewed at 4 years. Twenty-three (63.8%) of the 36 patients had erections sufficient for vaginal penetration, with a total mean +/- SD IIEF-5 score of 15.76 +/- 1.13. The other 50% (43 of 86) initiated sildenafil citrate for treatment of ED after seed implantation, with a minimal follow-up of 6 months. At 4 years, 32 (74%) of the 43 were responding positively to sildenafil citrate, with a total IIEF-5 score of 18.3 +/- 1.2. The mean EDITS +/- SD score was 76.5 +/- 3.2, and the spousal satisfaction rate was 72% (31 of 43). The dropout rate was 37% (16 of 43); 10 (63%) of the 16 discontinued because of a lack of efficacy, 3 (19%) because of a return of natural erections sufficient for vaginal penetration, and 3 (19%) discontinued because of side effects (headaches).
  
  
  CONCLUSIONS
  ED is a major long-term issue after (125)I seed radiotherapy, with a long-term potency rate of 29%. Sildenafil citrate improves erections in most patients after (125)I seed implantation.
authors.affiliation: Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors.forename: Rupesh
authors.initials: R
authors.lastname: Raina
authors.forename: Ashok
authors.initials: A
authors.lastname: Agarwal
authors.forename: Kush K
authors.initials: KK
authors.lastname: Goyal
authors.forename: Cheryl
authors.initials: C
authors.lastname: Jackson
authors.forename: James
authors.initials: J
authors.lastname: Ulchaker
authors.forename: Kenneth
authors.initials: K
authors.lastname: Angermeier
authors.forename: Eric
authors.initials: E
authors.lastname: Klein
authors.forename: Jay
authors.initials: J
authors.lastname: Ciezki
authors.forename: Craig D
authors.initials: CD
authors.lastname: Zippe
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects*; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology*; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000150:complications / Q000532:radiotherapy*; D011687:Purines; D012720:Severity of Illness Index; D012747:Sexual Partners / Q000523:psychology; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007457:Iodine Radioisotopes; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate